GOLPH3 and non-small cell lung carcinoma: Seven studies 11, 16, 24, 26-29 with 856 NSCLC patients were eligible to evaluate the correlation between overexpression of GOLPH3 and OS of cancer patients, including seven studies 11, 16, 24, 26-29 for univariate analysis and four studies 11, 16, 26, 28 for multivariate analysis (Table 4).